Serodiagnosis of Hepatitis B Surface Antigen and Anti Hepatitis C Virus among Hemodialysis Patients in Khartoum State- Sudan

Abstract

Background: Hepatitis B virus (HBV) is a hepatotropic virus that can establish a persistent and chronic infection in humans through immune energy. Hepatitis C virus (HCV) is a hepatotropic RNA virus that causes progressive liver damage. In hemodialysis (HD), blood is removed from the patient with needles and plastic tubing and pumped past the dialysis membrane. Poisons and toxins cross the dialysis membrane into the dialysate, which is then discarded, and the blood is returned to the patient. Objectives: The study aimed to detect HBsAg and anti-HCV in HD patients and the control group. Methods: A retrospective case-control, a hospital-based study was carried out on 110 participants 60 HD patients and 50 control, 60 males and 50 females, ages between 20 -39 years 27 participants and ages between 40-59 years 32 participants and ages more than 60 51 participants, ELISA method was used to detect HBsAg and anti-HCV in HD patients and control sera, the study was carried out during the period from August 2021 to January 2022. Results: In this study, the overall prevalence of HBV infection among HD patients and the control group was 26.3% (2/110), and among HD patients was 45 % (27/60), while it was 4% (2/50) among the control group any non – HD patient, co-patient, hospital staff and the overall prevalence of HCV was 1,8 % (2/110) and it was 3.3% (2/60) among the HD patients, 0% (0/50) among the control group. There was a significant association between HBV infection and HD (P value 0.019). Conclusions: The prevalence of HBV among HD patients was very high (45%). The results emphasize the need to carry out proactive tasks for early diagnosis by using highly sensitive and specific methods such as PCR technique, treatment of infected individuals, and vaccinating those with non-protective anti-HB antibodies to reduce morbidity and mortality in HD patients.